Skip to content
PICO Portalanswers from OpenAlex

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

PaperCitations, authors & open-access status

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer is a paper indexed in PICO Portal from OpenAlex.

How many citations does Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer have?

PICO Portalcitation count

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer has 312 citations in the OpenAlex counts PICO Portal stores.

When was Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer published?

PICO Portalyear

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer has 2019 year in the PICO Portal index.

What is the open-access status of Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer?

PICO Portaloa status

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer has green oa status in the PICO Portal index.

What is the DOI of Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer?

PICO Portaldoi

The DOI for Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer is on the source record.

What is the PMID of Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer?

PICO Portalpmid

The PMID for Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer is on the source record.

What is the OpenAlex record for Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer?

PICO Portalopenalex

The OpenAlex for Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial